Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof

Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof

The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tsai, Chia-Ling, Chen, Yeh, Hung, Mien-Chie, Yang, Wen-Hao, Hou, Mei-Hui, Chou, Yi-Zhen, Wang, Yu-Quan, Yang, Chia-Shin, Hung, Chian-Fang, Huang, Bao-Yue, Hung, Yu-Lin
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Tsai, Chia-Ling
Chen, Yeh
Hung, Mien-Chie
Yang, Wen-Hao
Hou, Mei-Hui
Chou, Yi-Zhen
Wang, Yu-Quan
Yang, Chia-Shin
Hung, Chian-Fang
Huang, Bao-Yue
Hung, Yu-Lin
description The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2021330661A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2021330661A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2021330661A13</originalsourceid><addsrcrecordid>eNqNjMsKwjAQAHvxIOo_LHi10Af0XotFD1qwqVcJ6UYDdTduqt8vSj_A0zAwzDySLiA0FpS2SPx8OcINbNmgF3w7gUbgpGXQk9YsoAT16OgGB7JoRsf0HbTluY2r5hJnUFIPR-yd0QNU_PAc3K9SdxRku4xmVg8BVxMX0breqWofo-crBq8NEo7Xrs2SLM3zpCjSMs3_qz6GN0Jr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof</title><source>esp@cenet</source><creator>Tsai, Chia-Ling ; Chen, Yeh ; Hung, Mien-Chie ; Yang, Wen-Hao ; Hou, Mei-Hui ; Chou, Yi-Zhen ; Wang, Yu-Quan ; Yang, Chia-Shin ; Hung, Chian-Fang ; Huang, Bao-Yue ; Hung, Yu-Lin</creator><creatorcontrib>Tsai, Chia-Ling ; Chen, Yeh ; Hung, Mien-Chie ; Yang, Wen-Hao ; Hou, Mei-Hui ; Chou, Yi-Zhen ; Wang, Yu-Quan ; Yang, Chia-Shin ; Hung, Chian-Fang ; Huang, Bao-Yue ; Hung, Yu-Lin</creatorcontrib><description>The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20211028&amp;DB=EPODOC&amp;CC=US&amp;NR=2021330661A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20211028&amp;DB=EPODOC&amp;CC=US&amp;NR=2021330661A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Tsai, Chia-Ling</creatorcontrib><creatorcontrib>Chen, Yeh</creatorcontrib><creatorcontrib>Hung, Mien-Chie</creatorcontrib><creatorcontrib>Yang, Wen-Hao</creatorcontrib><creatorcontrib>Hou, Mei-Hui</creatorcontrib><creatorcontrib>Chou, Yi-Zhen</creatorcontrib><creatorcontrib>Wang, Yu-Quan</creatorcontrib><creatorcontrib>Yang, Chia-Shin</creatorcontrib><creatorcontrib>Hung, Chian-Fang</creatorcontrib><creatorcontrib>Huang, Bao-Yue</creatorcontrib><creatorcontrib>Hung, Yu-Lin</creatorcontrib><title>Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof</title><description>The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjMsKwjAQAHvxIOo_LHi10Af0XotFD1qwqVcJ6UYDdTduqt8vSj_A0zAwzDySLiA0FpS2SPx8OcINbNmgF3w7gUbgpGXQk9YsoAT16OgGB7JoRsf0HbTluY2r5hJnUFIPR-yd0QNU_PAc3K9SdxRku4xmVg8BVxMX0breqWofo-crBq8NEo7Xrs2SLM3zpCjSMs3_qz6GN0Jr</recordid><startdate>20211028</startdate><enddate>20211028</enddate><creator>Tsai, Chia-Ling</creator><creator>Chen, Yeh</creator><creator>Hung, Mien-Chie</creator><creator>Yang, Wen-Hao</creator><creator>Hou, Mei-Hui</creator><creator>Chou, Yi-Zhen</creator><creator>Wang, Yu-Quan</creator><creator>Yang, Chia-Shin</creator><creator>Hung, Chian-Fang</creator><creator>Huang, Bao-Yue</creator><creator>Hung, Yu-Lin</creator><scope>EVB</scope></search><sort><creationdate>20211028</creationdate><title>Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof</title><author>Tsai, Chia-Ling ; Chen, Yeh ; Hung, Mien-Chie ; Yang, Wen-Hao ; Hou, Mei-Hui ; Chou, Yi-Zhen ; Wang, Yu-Quan ; Yang, Chia-Shin ; Hung, Chian-Fang ; Huang, Bao-Yue ; Hung, Yu-Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2021330661A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Tsai, Chia-Ling</creatorcontrib><creatorcontrib>Chen, Yeh</creatorcontrib><creatorcontrib>Hung, Mien-Chie</creatorcontrib><creatorcontrib>Yang, Wen-Hao</creatorcontrib><creatorcontrib>Hou, Mei-Hui</creatorcontrib><creatorcontrib>Chou, Yi-Zhen</creatorcontrib><creatorcontrib>Wang, Yu-Quan</creatorcontrib><creatorcontrib>Yang, Chia-Shin</creatorcontrib><creatorcontrib>Hung, Chian-Fang</creatorcontrib><creatorcontrib>Huang, Bao-Yue</creatorcontrib><creatorcontrib>Hung, Yu-Lin</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Tsai, Chia-Ling</au><au>Chen, Yeh</au><au>Hung, Mien-Chie</au><au>Yang, Wen-Hao</au><au>Hou, Mei-Hui</au><au>Chou, Yi-Zhen</au><au>Wang, Yu-Quan</au><au>Yang, Chia-Shin</au><au>Hung, Chian-Fang</au><au>Huang, Bao-Yue</au><au>Hung, Yu-Lin</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof</title><date>2021-10-28</date><risdate>2021</risdate><abstract>The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2021330661A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T20%3A30%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Tsai,%20Chia-Ling&rft.date=2021-10-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2021330661A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true